Macrocyclic compound and application thereof in medicine
By developing a macrocyclic compound as a 3Cl protease inhibitor, the problem of insufficient inhibitory activity of existing anti-3Clpro inhibitors on coronavirus was solved, effective inhibition of SARS-CoV-2 was achieved, and good pharmacokinetic properties and safety were achieved.
Patent Information
- Application Number
- CN202410098126.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-24
- Publication Date
- 2025-03-18
AI Technical Summary
The existing anti-3Clpro inhibitors have weak inhibitory activity on coronaviruses, especially SARS-CoV-2, and have problems such as single structure, weak enzyme inhibitory activity, and poor drug properties. It is difficult to effectively treat and prevent diseases or symptoms caused by coronavirus.
A macrocyclic compound was developed as an inhibitor of 3Cl protease, which has good inhibitory activity against coronaviruses, especially SARS-CoV-2, and has good pharmacokinetic properties, good solubility, good stability of liver microsomes, basically no inducible effect on liver drug enzymes and little toxicity.
This macrocyclic compound has good application prospects in the treatment and/or prevention of diseases or symptoms caused by coronaviruses, especially SARS-CoV-2, and can effectively inhibit the virus, and has good safety and drug properties.